| pubmed-article:18007551 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18007551 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:18007551 | lifeskim:mentions | umls-concept:C0023676 | lld:lifeskim |
| pubmed-article:18007551 | lifeskim:mentions | umls-concept:C0205474 | lld:lifeskim |
| pubmed-article:18007551 | lifeskim:mentions | umls-concept:C0400966 | lld:lifeskim |
| pubmed-article:18007551 | lifeskim:mentions | umls-concept:C0025598 | lld:lifeskim |
| pubmed-article:18007551 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:18007551 | lifeskim:mentions | umls-concept:C1948041 | lld:lifeskim |
| pubmed-article:18007551 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:18007551 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:18007551 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:18007551 | lifeskim:mentions | umls-concept:C1704419 | lld:lifeskim |
| pubmed-article:18007551 | lifeskim:mentions | umls-concept:C2003874 | lld:lifeskim |
| pubmed-article:18007551 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:18007551 | pubmed:dateCreated | 2007-11-16 | lld:pubmed |
| pubmed-article:18007551 | pubmed:abstractText | Insulin resistance plays an important role in the pathogenesis of NAFLD. Pharmacological treatment of patients with NAFLD is still evolving. Insulin sensitizing drugs like metformin may be effective in these patients. Twenty five adult patients with NAFLD who did not achieve normalization of alanine transaminases (ALT) after 6 months of lifestyle interventions and UDCA were treated with metformin 500mg tid for 6 months. Insulin resistance was determined by HOMA- IR. Liver function tests were done monthly and patients were defined having no response, partial response or complete biochemical response depending on the change in ALT. Results were compared with 25 patients with NAFLD from the same cohort treated only with lifestyle interventions (disease controls). | lld:pubmed |
| pubmed-article:18007551 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18007551 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18007551 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18007551 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18007551 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18007551 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18007551 | pubmed:issn | 1665-2681 | lld:pubmed |
| pubmed-article:18007551 | pubmed:author | pubmed-author:DhimanRadha... | lld:pubmed |
| pubmed-article:18007551 | pubmed:author | pubmed-author:DasAshimA | lld:pubmed |
| pubmed-article:18007551 | pubmed:author | pubmed-author:DusejaAjayA | lld:pubmed |
| pubmed-article:18007551 | pubmed:author | pubmed-author:BhansaliAnilA | lld:pubmed |
| pubmed-article:18007551 | pubmed:author | pubmed-author:BhadadaSanjay... | lld:pubmed |
| pubmed-article:18007551 | pubmed:author | pubmed-author:ChawlaYogesh... | lld:pubmed |
| pubmed-article:18007551 | pubmed:author | pubmed-author:ThumburuKiran... | lld:pubmed |
| pubmed-article:18007551 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18007551 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:18007551 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18007551 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18007551 | pubmed:pagination | 222-6 | lld:pubmed |
| pubmed-article:18007551 | pubmed:meshHeading | pubmed-meshheading:18007551... | lld:pubmed |
| pubmed-article:18007551 | pubmed:meshHeading | pubmed-meshheading:18007551... | lld:pubmed |
| pubmed-article:18007551 | pubmed:meshHeading | pubmed-meshheading:18007551... | lld:pubmed |
| pubmed-article:18007551 | pubmed:meshHeading | pubmed-meshheading:18007551... | lld:pubmed |
| pubmed-article:18007551 | pubmed:meshHeading | pubmed-meshheading:18007551... | lld:pubmed |
| pubmed-article:18007551 | pubmed:meshHeading | pubmed-meshheading:18007551... | lld:pubmed |
| pubmed-article:18007551 | pubmed:meshHeading | pubmed-meshheading:18007551... | lld:pubmed |
| pubmed-article:18007551 | pubmed:meshHeading | pubmed-meshheading:18007551... | lld:pubmed |
| pubmed-article:18007551 | pubmed:meshHeading | pubmed-meshheading:18007551... | lld:pubmed |
| pubmed-article:18007551 | pubmed:meshHeading | pubmed-meshheading:18007551... | lld:pubmed |
| pubmed-article:18007551 | pubmed:articleTitle | Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. | lld:pubmed |
| pubmed-article:18007551 | pubmed:affiliation | Departments of Hepatology. Postgraduate Institute of Medical Education and Research, Chandigarh, India. ajayduseja@yahoo.co.in | lld:pubmed |
| pubmed-article:18007551 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18007551 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18007551 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18007551 | lld:pubmed |
